Gabriela Lahaie Luna
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Gabriela Lahaie Luna has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Priya Bapat
Department of Ophthalmology, St. Michael's Hospital/Unity Health Toronto, Toronto, ON; Department of Ophthalmology & Vision Sciences, University of Toronto, Toronto, ON; Kensington Vision and Research Centre, Toronto, ON
2 shared publications- Rajeev H. Muni
Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada
2 shared publications Ryan H. Mason
Department of Ophthalmology, St. Michael's Hospital/Unity Health Toronto, Toronto, ON; Department of Ophthalmology & Vision Sciences, University of Toronto, Toronto, ON; Kensington Vision and Research Centre, Toronto, ON
2 shared publicationsSamuel A. Minaker
Department of Ophthalmology, St. Michael's Hospital/Unity Health Toronto, Toronto, ON; Department of Ophthalmology & Vision Sciences, University of Toronto, Toronto, ON; Kensington Vision and Research Centre, Toronto, ON
2 shared publicationsAdele Kim
School of Medicine, Queen's University, Kingston, ON
1 shared publicationAlex Gonzalez
Bascom Palmer Eye Institute, Department of Ophthalmology, Ophthalmic Biophysics Center, University of Miami Miller School of Medicine, Miami, FL
1 shared publication
Latest Publications
- 21 July 2024
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 60 (1) , e100-e116
Changes in aqueous and vitreous inflammatory cytokine levels in nonproliferative diabetic retinopathy: systematic review and meta-analysis
- 21 July 2024
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 60 (1) , e100-e116
Changes in aqueous and vitreous inflammatory cytokine levels in nonproliferative diabetic retinopathy: systematic review and meta-analysis
- Open Access
- 16 December 2023
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 59 (3) , e287-e289
Pigmented paravenous retinochoroidal atrophy in an infant with unilateral macular involvement: case report and literature review
- 16 December 2023
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 59 (3) , e287-e289
Open AccessPigmented paravenous retinochoroidal atrophy in an infant with unilateral macular involvement: case report and literature review
- 1 June 2021
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 56 (3) , 191-196
Validating the use of a stereoscopic robotized teleophthalmic drone slit lamp
- 1 June 2021
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 56 (3) , 191-196
Validating the use of a stereoscopic robotized teleophthalmic drone slit lamp
- 4 May 2021
- Published by Wiley in Acta Ophthalmologica
- Vol. 100 (1) , E53-E70
Changes in aqueous and vitreous inflammatory cytokine levels in diabetic macular oedema: a systematic review and meta‐analysis
Diabetic macular oedema (DME) is considered a chronic inflammatory disease associated with aberrations in many intraocular cytokines. Studies assessing the role of these cytokines as biomarkers in the diagnosis and management of DME have demonstrated inconsistent findings. We quantitatively summarized data related to 116 candidate aqueous and vitreous inflammatory cytokines as biomarkers in DME. A systematic search without year limitation was performed up to 19 October 2020. Studies were included if they provided data on aqueous or vitreous cytokine concentrations in patients with DME. Effect sizes were generated as standardized mean differences (SMDs) of cytokine concentrations between patients with DME and controls. Data were extracted from 128 studies that included 4163 study eyes with DME and 1281 control eyes. Concentrations (standard mean difference, 95% confidence interval and p‐value) of aqueous IL‐6 (1.28, 0.57–2.00, p = 0.004), IL‐8 (1.06, 0.74–1.39, p < 0.00001), MCP‐1 (1.36, 0.57–2.16, p = 0.0008) and VEGF (1.31, 1.01–1.62, p < 0.00001) and vitreous VEGF (2.27, 1.55–2.99, p < 0.00001) were significantly higher in patients with DME (n = 4163) compared to healthy controls (n = 1281). No differences, failed sensitivity analyses or insufficient data were found between patients with DME and healthy controls for the concentrations of the remaining cytokines. This analysis implicates multiple cytokine biomarker candidates other than VEGF in DME and clarifies previously reported inconsistent associations. As the therapeutic options for DME expand to include multiple agents with multiple targets, it will be critical to manage the treatment burden with tailored therapy that optimizes outcomes and minimizes treatment burden. Intraocular cytokines have the promise of providing a robust individualized assessment of disease status and response to therapy. We have identified key candidate cytokines that may serve as biomarkers in individualized treatment algorithms.
- 4 May 2021
- Published by Wiley in Acta Ophthalmologica
- Vol. 100 (1) , E53-E70
Changes in aqueous and vitreous inflammatory cytokine levels in diabetic macular oedema: a systematic review and meta‐analysis
Diabetic macular oedema (DME) is considered a chronic inflammatory disease associated with aberrations in many intraocular cytokines. Studies assessing the role of these cytokines as biomarkers in the diagnosis and management of DME have demonstrated inconsistent findings. We quantitatively summarized data related to 116 candidate aqueous and vitreous inflammatory cytokines as biomarkers in DME. A systematic search without year limitation was performed up to 19 October 2020. Studies were included if they provided data on aqueous or vitreous cytokine concentrations in patients with DME. Effect sizes were generated as standardized mean differences (SMDs) of cytokine concentrations between patients with DME and controls. Data were extracted from 128 studies that included 4163 study eyes with DME and 1281 control eyes. Concentrations (standard mean difference, 95% confidence interval and p‐value) of aqueous IL‐6 (1.28, 0.57–2.00, p = 0.004), IL‐8 (1.06, 0.74–1.39, p < 0.00001), MCP‐1 (1.36, 0.57–2.16, p = 0.0008) and VEGF (1.31, 1.01–1.62, p < 0.00001) and vitreous VEGF (2.27, 1.55–2.99, p < 0.00001) were significantly higher in patients with DME (n = 4163) compared to healthy controls (n = 1281). No differences, failed sensitivity analyses or insufficient data were found between patients with DME and healthy controls for the concentrations of the remaining cytokines. This analysis implicates multiple cytokine biomarker candidates other than VEGF in DME and clarifies previously reported inconsistent associations. As the therapeutic options for DME expand to include multiple agents with multiple targets, it will be critical to manage the treatment burden with tailored therapy that optimizes outcomes and minimizes treatment burden. Intraocular cytokines have the promise of providing a robust individualized assessment of disease status and response to therapy. We have identified key candidate cytokines that may serve as biomarkers in individualized treatment algorithms.